SenesTech, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Edell
- Full Time Employees
- 24
- Sector
- Basic Materials
- Industry
- Chemicals - Specialty
- Address
- 13430 North Dysart Road Suite 105 Surprise AZ United States of America 85379
- IPO Date
- Dec 7, 2016
- CIK
- 0001680378
- Website
- senestech.com
- Similar Companies
- Business
- SenesTech, Inc. is a biotechnology company specializing in the development and commercialization of innovative, environmentally-friendly pest management products primarily targeting the agricultural and urban pest control markets. The company focuses on the production and sale of its flagship product, ContraPest®, an oral baits-based rodent fertility control technology designed to humanely and effectively reduce rat populations. SenesTech also offers related pest control solutions and has expanded its product portfolio to include integrated pest management systems. Founded in 2007 and headquartered in Phoenix, Arizona, SenesTech serves customers across the United States and has ongoing efforts to expand its geographic footprint. Recent major developments for SenesTech include strategic partnerships aimed at enhancing distribution and deployment of ContraPest and related pest control products. The company has also been advancing research and development initiatives to introduce new pest management products and expand applications of its fertility control technology. These efforts include collaborations with public and private sector entities to address pest challenges in various environments. SenesTech continues to focus on sustainable and humane pest control methods as a core part of its growth strategy. SenesTech operates primarily within the biotechnology and pest management industry segments. Its target customers include agricultural producers, municipalities, food service providers, and pest control professionals. The company leverages its proprietary technology for environmentally responsible pest population control and aims to replace traditional toxic rodenticides with fertility control alternatives. SenesTech's business model emphasizes research-driven innovation, strategic alliances, and expanding market penetration in the United States and eventually internationally. The company is publicly traded under the ticker SNES.
Financial Survey: Senestech (NASDAQ:SNES) & Chemtrade Logistics Income Fund (OTCMKTS:CGIFF)
SenesTech, Inc. (SNES) Q2 2026 Earnings Call Transcript
Senestech Q2 Earnings Call Highlights
SenesTech Reports Record Q2 2026 Revenue and Gross Margin as E-commerce Growth Accelerates
SenesTech Adds Assessment Services to Help B2B Customers Better Understand Rodent Infestations
SenesTech Active Subscriber Base More Than Doubles as E-commerce Strategy Gains Momentum
SenesTech to Report Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
SenesTech's Evolve® Delivers Significant Reduction in Rodent Damage at Texas Agricultural Operation
SenesTech Appoints Jack Karabees as Executive Vice President of Sales
SenesTech Expands Distribution of Evolve® Rodent Birth Control™ into Bermuda
SenesTech Announces Amendment to Equity Incentive Plan Proposal
SenesTech to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
SenesTech, Inc. (SNES) Q1 2026 Earnings Call Transcript
SenesTech Reports Record Direct-to-Consumer and Subscription Growth Following Strategic E-Commerce Transition
SenesTech to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
SenesTech Appoints Michael Edell as President and Chief Executive Officer to Drive Revenue Growth and Scalable Sales Channels
Senestech, Inc. (NASDAQ:SNES) Short Interest Update
Head-To-Head Analysis: Senestech (NASDAQ:SNES) vs. RBC Life Sciences (OTCMKTS:RBCL)
Senestech, Inc. (NASDAQ:SNES) Short Interest Update
SenesTech, Inc. (SNES) Q4 2025 Earnings Call Transcript